Trial reportBlood2006
Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2.
Trial report in Blood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- T cell functionality in HIV-1, HIV-2 and dually infected individuals: correlates of disease progression and immune restoration.Clinical and experimental immunology · 2019Trial
- Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2.The Journal of infectious diseases · 2008Trial
- Type I Natural Killer T Cells as Key Regulators of the Immune Response to Infectious Diseases.Clinical microbiology reviews · 2021Review
- Mucosal Immunity in HIV/SIV Infection: T Cells, B Cells and Beyond.Current immunology reviews · 2019Article
- Herpes Simplex Virus 1 Specifically Targets Human CD1d Antigen Presentation To Enhance Its Pathogenicity.Journal of virology · 2018Article
- CD1-Restricted T Cells During Persistent Virus Infections: "Sympathy for the Devil".Frontiers in immunology · 2018Review
- LatentFrontiers in immunology · 2018Article
- Functional Invariant Natural Killer T Cells Secreting Cytokines Are Associated With Non-Progressive Human Immunodeficiency Virus-1 Infection but Not With Suppressive Anti-Retroviral Treatment.Frontiers in immunology · 2018Article
- Negative Checkpoint Regulatory Molecule 2B4 (CD244) Upregulation Is Associated with Invariant Natural Killer T Cell Alterations and Human Immunodeficiency Virus Disease Progression.Frontiers in immunology · 2017Article
- Human Immunodeficiency Virus Infection and Host Defense in the Lungs.Seminars in respiratory and critical care medicine · 2016Review
- Interleukins 15 and 12 in combination expand the selective loss of natural killer T cells in HIV infection in vitro.Clinical and experimental medicine · 2015Article
- Regulation of NKT Cell Localization in Homeostasis and Infection.Frontiers in immunology · 2015Review
- Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression.Frontiers in immunology · 2014Review
- Will loss of your MAITs weaken your HAART [corrected]?AIDS (London, England) · 2013Article
- Loss of effector and anti-inflammatory natural killer T lymphocyte function in pathogenic simian immunodeficiency virus infection.PLoS pathogens · 2012Article
- HIV-1 Vpu interference with innate cell-mediated immune mechanisms.Current HIV research · 2012Review
- Bystander activation of iNKT cells occurs during conventional T-cell alloresponses.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2012Article
- Invariant NKT cells: regulation and function during viral infection.PLoS pathogens · 2012Review
- Herpes simplex virus 1 glycoprotein B and US3 collaborate to inhibit CD1d antigen presentation and NKT cell function.Journal of virology · 2011Article
- Impairment of CD1d-restricted natural killer T cells in chronic HIV type 1 clade C infection.AIDS research and human retroviruses · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Innate CD1d-restricted natural killer T (NKT) cells are infected and lost in HIV-1-infected patients, and this could contribute to HIV-1 pathogenesis because NKT cells play an important role in directing both adaptive and innate immunity. Administration of interleukin-2 (IL-2) to HIV-1-infected patients leads to substantial and sustained CD4+ T-cell expansion, involving both naive and memory cells. We investigated whether IL-2 treatment could restore the NKT cell compartment in patients with primary HIV-1 infection. We show that IL-2 combined with effective antiretroviral therapy (ART) resulted in significant expansion of CD1d-restricted NKT cells. Expansion occurred in both the CD4- and CD4+ subsets of NKT cells, and expanded cells expressed the CD161 maturation marker while expression of the HIV coreceptor CCR5 was reduced. These data indicate that IL-2 treatment in combination with effective ART is beneficial for the restoration of innate NKT cell immunity in patients with primary HIV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.